Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, announced today that long-term safety and patient reported outcomes for ZORVOLEX® (diclofenac) capsules in patients with osteoarthritis (OA) pain will be presented at the upcoming American College of Rheumatology 2014 Annual Meeting, November 14 - 19 in Boston1,2. ZORVOLEX, a nonsteroidal anti-inflammatory drug (NSAID), was approved by the United States Food and Drug Administration (FDA) in August 2014 for the management of OA pain and in October 2013 for the treatment of mild to moderate acute pain in adults.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
